MRK dividend yield: 3.25%. EPRT dividend yield: 4.00%. Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s. EPRT is a dividend-paying stock. Use this calculator to estimate your future dividend income, DRIP compounding returns, and passive income potential from investing in EPRT shares.
Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.
EPRT is a dividend-paying stock. Use this calculator to estimate your future dividend income, DRIP compounding returns, and passive income potential from investing in EPRT shares.
Is MRK or EPRT better for dividend income in 2026?
MRK currently offers a 3.25% yield (3.08/share/year) while EPRT offers 4.00% (2.00/share/year). EPRT provides higher current income. However, MRK has grown its dividend faster (8.2% 5Y CAGR), which may lead to better long-term income through compounding.
How much would $10,000 in MRK vs EPRT earn per year?
With $10,000 invested today: MRK pays approximately $325/year. EPRT pays approximately $400/year. With DRIP reinvestment over 10 years, these grow to $950/year (MRK) and $899/year (EPRT).
Does MRK or EPRT pay monthly dividends?
MRK pays quarterly dividends. EPRT pays quarterly dividends. Neither pay monthly — both use a quarterly schedule, which is preferred by investors who need regular cash flow.
📬
Get this MRK vs EPRT comparison by email
Save your analysis + get weekly dividend insights. Free forever.